How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Novo Nordisk, the Danish pharmaceutical giant that developed the groundbreaking weight-loss drug Ozempic, saw its dominance in the GLP-1 market challenged by Eli Lilly's entry into the arena. Despite Ozempic's massive success, Eli Lilly's strategic moves and faster market entry have shifted the competitive landscape. This shift underscores the intense global competition and raises questions about Europe's ability to maintain its edge in high-stakes industries. The outcome also highlights how quickly market leaders can be overtaken if they don't keep pace with innovation and market dynamics.